New combo aims to stop lymphoma relapse after powerful treatments

NCT ID NCT06242834

Ongoing Disease control Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This phase II trial tests whether combining pembrolizumab (Keytruda) and tazemetostat can help prevent aggressive B-cell lymphoma from returning after patients have already received a stem cell transplant or CAR-T cell therapy. The study enrolls 32 adults and will measure how long they stay cancer-free. The goal is to see if this drug pair can overcome immune resistance that often allows the cancer to come back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab and tazemetostat
What this could lead to: If it works, this could offer a new way to prevent lymphoma from returning after stem cell or CAR-T therapy.
What could go wrong: This is a small, early-phase trial with only 32 participants, so results may not apply widely. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma B-cell neoplasm B-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Northwestern University

Chicago, Illinois, 60611, United States
University of Iowa

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.